Gene therapy for inherited corneal dystrophy
Part of Brain & nervous system, Eyes & vision, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests a new gene therapy to treat a type of corneal dystrophy caused by a faulty gene. It aims to improve symptoms and slow the disease's progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with corneal dystrophy caused by a TGFBI gene mutation (confirmed by genetic testing).
- You have noticeable symptoms from the corneal dystrophy.
- You have not had gene therapy in either eye before.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You do not have other eye conditions or recent serious health issues that could affect the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a new cell-based treatment (C.001) for inherited retinal diseases that affect the back of the eye. The treatment may help slow vision loss or improve sight in people with geographic atrophy or Stargardt disease.
This trial tests an investigational gene therapy called ZVS101e for people with Bietti's crystalline dystrophy (BCD), a rare inherited eye disease. It aims to see if the treatment can help slow vision loss or improve vision.
This trial tests a new gene therapy called VG901, given as an injection into the eye, for people with retinitis pigmentosa caused by a specific genetic change in the CNGA1 gene. The goal is to see if it is safe and tolerable.
This early-stage trial tests a gene therapy aimed at treating inherited retinal dystrophy caused by changes in the RPE65 gene on both copies. It may help slow vision loss or improve eye function, but the study is mainly about safety and learning how the treatment works.
This trial tests a simple cell treatment for a swollen cornea caused by cataract surgery. It aims to help your cornea become clear again without a full transplant.
This trial tests a new gene therapy called SB-007 for people with Stargardt disease (STGD1). It is given as an injection under the retina to see if it is safe and can help slow vision loss.
Hear when a new Hereditary Corneal Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.